Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Invivyd Inc IVVD

Healthcare Biotechnology
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IVVD)

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA(TM)

GlobeNewswire 4 days ago

Invivyd Announces CEO Transition

GlobeNewswire 7 days ago

Invivyd Provides PEMGARDA(TM) Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

GlobeNewswire April 4, 2024

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire March 28, 2024

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

GlobeNewswire March 22, 2024

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA(TM) (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

GlobeNewswire March 22, 2024

Grabar Law Office Investigates Claims on Behalf of Shareholders of Invivyd, Inc. (IVVD) f/k/a Adagio Therapeutics (ADGI)

Newsfile February 29, 2024

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire February 5, 2024

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

GlobeNewswire January 3, 2024
View More News ››

Opinion & Analysis (NDAQ:IVVD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IVVD)

ADGI APPOINT DAVID HERING AS INTERIM CEO

EOM
Humanist - February 23, 2022

ADGI:TO ANALYZE DATA FROM TRIALS GLOBALLY/RESULTS END MARCH

BRIEF-Adagio Therapeutics Outlines Strategic Initiatives For Co's ADG20 Program   Published by  Reuters 2022 Feb...
Humanist - February 22, 2022

ADGI CEO RESIGNS/REPLACED BY COO INTERMILY

Adagio Therapeutics Announces CEO Succession Plan   https://finance.yahoo.com/news/adagio-therapeutics-announces-ceo-succession...
Humanist - February 19, 2022

Fekb 09, 2022

Nice price run up and volume. What will 4pm and rest of week say. What are we waiting to say ADGI...
petrojell - February 9, 2022

5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS

$ADGI $CYTK $PHAT $AGIO $ICPT   Clinical-Stage companies offer an exciting investment opportunity with massive upside potential...
AviseAnalytics - February 8, 2022

any thoughts whats driving adgi tdy?

thx if you're reading this, would welcome all opinions
Humanist - February 7, 2022
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »